WHAT IS A LIQUID STICK-PACK?

 

The stick-pack is a unit dosage form that can be used to contain and deliver liquid health products for oral and topical use.

The packaging protects the contents from moisture, oxygen and light. Thanks to its small size and compactness, the unit-dose is user-friendly and very practical for everyday life.

PATIENT BENEFITS

  • “I have been waiting for this type of product on the market for a very long time. When you travel, when you have to go out, it is absolutely ideal. It allows you not to interrupt a treatment, simply because the usual product cannot be carried.”
  • “These ready-to-use formulas are suitable for everyone: children, teenagers, pregnant women and older people.”

READY TO
USE

68%

68% appreciate the convenience
of the form: ready-to-use,
which can be taken
anywhere and
at any time.

THE RIGHT DOSE
FOR EVERYONE

75% – three quarters (¾)

of the population would be willing to purchase ready-to-use forms for their loved ones (including children and seniors).

Source : National representative study in 5 EU countries (1000 persons by country), GFK and Unither, 2018

BENEFITS OF THE LIQUID STICK-PACK:

  • Safety of use
  • Delivery of the right dose
  • Ready-to-use, robust and easy to carry
  • Good product conservation
  • Improved formulation (taste masking, and less or no preservatives)
  • Possibility for the patient to purchase a stick-pack by unit

UNISTICK®: STICK-PACK BY UNITHER

The stick-pack is suitable for packaging a wide range of health products in drinkable or topical liquid form.

1 ml to 15 ml

Solutions, suspensions, emulsions and gels

Assembly of several components to guarantee and ensure the stability of the product over time

Drugs, Medical devices, Food supplements, Cosmetics

1 to 1500 cP

Suitable for all therapeutic areas (e.g. analgesics, gastroenterology, cardiovascular diseases, central nervous system, orphan diseases, cough and cold, etc.)

Individual stick-pack packaging helps to preserve products that are sensitive to oxygen (preparation and filling under nitrogen) or to light thanks to its barrier effect. Certain formulation options exist such as taste masking or preservative-free formulation.

OUR SITES

Unither Pharmaceuticals is a CDMO specializing in liquid stick-packs, offering support from formulation to industrial scale-up. The unique expertise of our multidisciplinary and international teams will meet all regulatory, development and manufacturing needs in France, the United States and Brazil.

COLOMIERS (France)

  • Capacity: 420 million sticks / year
  • Filling: 1 ml to 15 ml
  • Lines: 4 (1 pilot line and 3 industrial lines)
  • Authorizations: ANSM, EMA, Anvisa, KFDA, Health Canada, MHRA, South Korea, etc.

ROCHESTER (United States)

  • Capacity: 250 million sticks / year
  • Filling: 2.5 ml to 10 ml
  • Lines: 2 (1 pilot line and 1 industrial line)
  • Authorizations: MHRA, FDA, ANVISA, Health Canada, Turkey, Mexico, etc.

BARRETOS (Brazil)

  • Capacity: 70 million sticks / year
  • Filling: 5 ml to 15 ml
  • Lines: 3 (1 industrial line and 2 pilot lines)
  • Authorizations: ANVISA

COLLABORATIONS ALL OVER THE WORLD

100

SKUs

+30

Customers

50

Countries where
our products
are sold

Two types of collaboration:

We offer our customers two types of collaboration: the
development and manufacturing of new products based
on their specifications, and/or a turnkey product from our product list.

1

Contract development
and manufacturing
for strategic subcontracting

2

Turnkey products and dossiers
for licensing-in

DISCOVER OUR LATEST NEWS

Pharnext moves production of its pending drug PXT303 to the United States

Published on 01/26/2023 (AOF) – Pharnext, a biotech company developing new treatments for neurodegenerative diseases without satisfactory therapeutic solutions, today announced that it has successfully moved the manufacture of PXT3003, its drug for Charcot-Marie-Tooth disease type 1A (CMT1A), to Unither Pharmaceuticals’ U.S. plant in Rochester, New York, from Unither’s plant in Colomiers (Haute-Garonne, France). With... View Article

Unither Pharmaceuticals has completed the purchase of the Novartis site located at Butantã, in São Paulo, Brazil.  

Unither Pharmaceuticals has completed the purchase of the Novartis site located at Butantã, in São Paulo, Brazil.‑‑ Paris (France), 11/28/2022 – Unither Pharmaceuticals, the world’s leading manufacturer of sterile unit-dose products, recently acquired the Novartis plant in São Paulo, Brazil, as a new step in its industrial expansion in Brazil. «This acquisition enables us to... View Article

Jean-François Hilaire: newly appointed CEO of Unither Pharmaceuticals

Paris (France), November 14, 2022 – Unither Pharmaceuticals’ Supervisory Board appoints Jean-François Hilaire as Chief Executive Officer. As Executive Chairman, Eric Goupil will continue to play an important role in strategic decisions. The Group has grown sales by an average of 14% per year since 2000, reaching a production record of more than 3 billion... View Article